Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

DNMT3A R882 mutations promote chemoresistance and residual disease in AML

EHA 2015

11 - 14 Jun 2015

Published: 12 Jun 2015

Views: 3117

Rating:

Save

Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Olga Guryanova presents, at a press conference at EHA 2015, the findings of her work looking at the role of mutant DNMT3A in acute myeloid leukaemia (AML) pathogenesis and chemoresistance.

Read the news story for more.

Related Videos

New classification for identifying HR myeloma based on cytogenetic abnormalities

Dr Jill Corre - IUCT Oncopole, Toulouse, France

New classification for identifying HR myeloma based on cytogenetic abnormalities ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard...

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )

A randomised trial of the FLT3 inhibitor gilteritinib as post-transplant...

Dr Mark Levis - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center...

A randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML ( Dr Mark Levis - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes...

Dr Joshua Choe - Columbia University, New York City, USA

Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death ( Dr Joshua Choe - Columbia University, New York City, USA )

More from ecancer